RETA-PEN 20mg
฿11,000.00
Retatrutide is one of the most promising new weight-loss and metabolic health drugs currently in clinical development. Unlike existing GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) or dual agonists like tirzepatide (Mounjaro, Zepbound), Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. This unique mechanism has shown unprecedented results in early clinical trials, with participants losing over 24% of their body weight in less than a year at the highest studied doses
In stock
75 CLICKS = 5MG
Retatrutide (also known as LY-3437943) is an experimental medication developed by Eli Lilly that is being studied as a next-generation treatment for obesity, overweight, and related metabolic conditions such as type 2 diabetes. It represents a new class of therapies called “triple agonists,” meaning it simultaneously activates three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This combined activity helps regulate appetite, improve insulin sensitivity, slow gastric emptying to promote fullness, and enhance fat burning.
Key Points:
→ Retatrutide is given as a once-weekly subcutaneous injection.
→ Stepwise escalation is critical to reduce gastrointestinal intolerance.
→ Most participants in trials reached 8–12 mg weekly, which delivered the strongest results
→ Dosing protocols may be refined in Phase 3 and post-approval, but gradual titration will remain the standard.
Common Side Effects :
Across Phase 2 trials, participants experienced dose-dependent GI symptoms that are characteristic of GLP-1 receptor agonists:
- Nausea — most frequent, especially during dose escalation
- Vomiting — typically mild to moderate, subsiding with continued use
- Diarrhea and constipation — fluctuating depending on individual tolerance
- Abdominal discomfort — transient and often improved over time
| Reta-Pem | Retatrutide Injection Pen 10mg |
|---|
Related products
